Journal article
MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with motor neuron loss as a defining feature. Despite significant effort, therapeutic breakthroughs have been modest. MN-166 (ibudilast) has demonstrated neuroprotective action by various mechanisms: inhibition of proinflammatory cytokines and macrophage migration inhibitory factor, phosphodiesterase inhibition, and attenuation of glial cell activation in models of ALS. …
Authors
Oskarsson B; Maragakis N; Bedlack RS; Goyal N; Meyer JA; Genge A; Bodkin C; Maiser S; Staff N; Zinman L
Journal
Neurodegenerative Disease Management, Vol. 11, No. 6, pp. 431–443
Publisher
Taylor & Francis
Publication Date
December 2021
DOI
10.2217/nmt-2021-0042
ISSN
1758-2024